ValenzaBio nabs $70m Series A

ValenzaBio Inc, a developer of monoclonal antibody therapeutics for autoimmune and inflammatory indications, has closed $70 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this